This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BioMarin Pharmaceutical Inc.
Drug Names(s): GALNS, recombinant human N-acetylgalactosamine-6-sulfate sulfatase (rhGALNS), BMN 110, elosulfase alfa
Description: BMN 110 is an enzyme replacement of N-acetylgalactosamine-6-sulfate sulfatase (GALNS).
MPS IVA, also known as Morquio A Syndrome, is a disorder characterized by deficient activity of GALNS causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance.
Additional information available to subscribers only: